Profile data is unavailable for this security.
About the company
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
- Revenue in USD (TTM)107.27m
- Net income in USD6.65m
- Incorporated1997
- Employees574.00
- LocationGyre Therapeutics Inc12770 High Bluff Drive, Suite 150SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 567-7770
- Fax+1 (302) 636-5454
- Websitehttps://www.gyretx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Replimune Group Inc | 0.00 | -314.85m | 658.93m | 479.00 | -- | 3.02 | -- | -- | -3.44 | -3.44 | 0.00 | 2.64 | 0.00 | -- | -- | 0.00 | -67.19 | -33.04 | -75.03 | -35.07 | -- | -- | -- | -- | -- | -- | 0.2565 | -- | -- | -- | -14.60 | -- | 0.4456 | -- |
| enGene Holdings Inc | 0.00 | -117.30m | 665.83m | 45.00 | -- | 3.08 | -- | -- | -2.29 | -2.29 | 0.00 | 3.22 | 0.00 | -- | -- | 0.00 | -44.05 | -- | -48.27 | -- | -- | -- | -- | -- | -- | -- | 0.1221 | -- | -- | -- | -112.73 | -- | 50.55 | -- |
| Cullinan Therapeutics Inc | 0.00 | -216.81m | 690.60m | 111.00 | -- | 1.53 | -- | -- | -3.68 | -3.68 | 0.00 | 7.64 | 0.00 | -- | -- | 0.00 | -38.12 | -16.54 | -40.13 | -17.34 | -- | -- | -- | -1,797.10 | -- | -- | 0.00 | -- | -- | -- | -9.28 | -- | -- | -- |
| Upstream Bio Inc | 2.80m | -122.77m | 691.69m | 52.00 | -- | 1.83 | -- | 247.12 | -2.30 | -2.30 | 0.0527 | 7.01 | 0.009 | -- | 4.34 | 53,826.92 | -39.18 | -- | -40.67 | -- | -- | -- | -4,366.77 | -- | -- | -- | 0.00 | -- | -0.4202 | -- | -99.70 | -- | -- | -- |
| YD Bio Ltd | -100.00bn | -100.00bn | 691.81m | 5.00 | -- | 135.97 | -- | -- | -- | -- | -- | 0.0722 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.36 | -- | 0.0124 | -- | 45.76 | -- | -10,509.73 | -- | -- | -- |
| LB Pharmaceuticals Inc | 0.00 | -18.80m | 696.55m | 16.00 | -- | 1.99 | -- | -- | -0.82 | -0.82 | 0.00 | 12.26 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -905.61 | -- | -- | -- |
| Kura Oncology Inc | 104.03m | -216.88m | 697.88m | 192.00 | -- | 2.88 | -- | 6.71 | -2.48 | -2.48 | 1.19 | 2.79 | 0.1844 | -- | -- | 541,817.70 | -38.45 | -26.38 | -44.88 | -28.06 | -- | -- | -208.48 | -1,266.72 | -- | -- | 0.0384 | -- | -- | -- | -13.99 | -- | -- | -- |
| Gyre Therapeutics Inc | 107.27m | 6.65m | 710.76m | 574.00 | 121.15 | 6.97 | 50.41 | 6.63 | 0.0646 | 0.0646 | 1.09 | 1.12 | 0.7537 | 0.6368 | 4.73 | 186,872.80 | 8.30 | -53.99 | 12.90 | -82.36 | 95.48 | 89.58 | 11.01 | -88.61 | 5.64 | -- | 0.00 | -- | -6.78 | -- | 113.00 | -- | 117.68 | -- |
| Fulcrum Therapeutics Inc | 0.00 | -71.11m | 716.44m | 45.00 | -- | 2.96 | -- | -- | -1.14 | -1.14 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -28.80 | -35.63 | -30.41 | -38.94 | -- | -- | -- | -314.68 | -- | -- | 0.00 | -- | 2,752.05 | -- | 90.01 | -- | -20.09 | -- |
| Jade Biosciences Inc | 0.00 | -65.26m | 730.35m | 4.00 | -- | 2.69 | -- | -- | -11.45 | -11.45 | 0.00 | 5.50 | 0.00 | -- | -- | 0.00 | -44.48 | -47.29 | -50.06 | -50.63 | -- | -- | -- | -- | -- | -320.04 | 0.00 | -- | -- | -- | 7.80 | -- | -- | -- |
| Personalis Inc | 69.10m | -73.88m | 745.07m | 229.00 | -- | 4.34 | -- | 10.78 | -0.8761 | -0.8761 | 0.8189 | 1.93 | 0.2863 | 7.71 | 4.96 | 301,759.80 | -30.61 | -29.82 | -36.03 | -34.69 | 26.67 | 28.44 | -106.92 | -105.71 | 4.69 | -- | 0.0133 | -- | 15.15 | 5.35 | 24.94 | -- | -28.17 | -- |
| Annexon Inc | 0.00 | -208.88m | 750.19m | 99.00 | -- | 3.70 | -- | -- | -1.39 | -1.39 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -68.11 | -42.65 | -76.07 | -45.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.95 | -- | -43.78 | -- |
| MiMedx Group Inc | 393.44m | 40.83m | 753.84m | 837.00 | 18.64 | 3.15 | 13.59 | 1.92 | 0.273 | 0.273 | 2.63 | 1.61 | 1.40 | 2.79 | 5.95 | 470,062.10 | 14.51 | 2.94 | 17.63 | 3.89 | 81.99 | 83.00 | 10.38 | 2.07 | 3.95 | -- | 0.0708 | -- | 8.52 | 3.12 | -24.73 | -- | -5.37 | -- |
| Arvinas Inc | 312.30m | -58.50m | 760.09m | 430.00 | -- | 1.48 | -- | 2.43 | -0.8048 | -0.8048 | 4.30 | 7.97 | 0.3105 | -- | 22.63 | 726,279.10 | -5.82 | -20.58 | -7.36 | -25.05 | -- | -- | -18.73 | -211.50 | -- | -- | 0.0007 | -- | 235.54 | 43.71 | 45.85 | -- | -22.02 | -- |
| SS Innovations International Inc | 33.57m | -17.11m | 760.93m | 378.00 | -- | 19.19 | -- | 22.66 | -0.0959 | -0.0959 | 0.1822 | 0.2048 | 0.6253 | 1.19 | 5.09 | 88,820.32 | -31.86 | -77.47 | -50.87 | -137.45 | 48.25 | 23.69 | -50.96 | -169.09 | 1.34 | -- | 0.2025 | -- | 251.46 | -- | 8.27 | -- | 67.53 | -- |
| Kalvista Pharmaceuticals Inc | 15.12m | -210.31m | 764.26m | 270.00 | -- | 44.96 | -- | 50.55 | -3.95 | -3.95 | 0.2838 | 0.3363 | 0.0604 | -- | 1.51 | 55,992.59 | -84.00 | -49.86 | -97.02 | -54.21 | 87.95 | -- | -1,391.14 | -- | 7.21 | -82.77 | 0.9412 | -- | -- | -- | -44.85 | -- | 33.39 | -- |
Data as of Feb 13 2026. Currency figures normalised to Gyre Therapeutics Inc's reporting currency: US Dollar USD
3.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.05m | 1.16% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 599.66k | 0.66% |
| Geode Capital Management LLCas of 30 Sep 2025 | 374.62k | 0.41% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 182.75k | 0.20% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 162.92k | 0.18% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 138.08k | 0.15% |
| Charles Schwab Investment Management, Inc.as of 30 Sep 2025 | 123.39k | 0.14% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 116.34k | 0.13% |
| State of Wisconsin Investment Boardas of 30 Sep 2025 | 39.00k | 0.04% |
| Millennium Management LLCas of 30 Sep 2025 | 35.75k | 0.04% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
